摘要:
The present invention is directed to a formulation for treating cancer comprising an androgen receptor signaling inhibitor and a B-cell-lymphoma-2 inhibitor, which may further comprising a Bromodomain-and-Extra-Terminal protein inhibitor or a phosphoinositide 3-kinase inhibitor.
摘要:
Ultrasound radiation using a single tone burst pulse is applied to a selected location in a tissue region. The induced shear wave is detected in the region and its spectral distribution is calculated and analyzed. This detection may be repeated with other excitation pulses having different widths or different shapes at the same location. The spectral analysis of the detected shear wave is performed according to a nonlinear shear model for solving nonlinearity and viscoelasticity of the tissue at a single location. The detection location can be at one point at a time for imaging two-dimensional or three-dimensional tissue nonlinearities and shear wave properties including nonlinear magnitude variations, nonlinear phase variations, nonlinear coefficients, and viscoelasticity. The induced shear wave are detected at multiple locations along the shear propagation directions for calculating different shear group velocities and different shear phase velocities using different excitation pulses, and calculating nonlinearity and viscoelasticity.
摘要:
Anti-wear and/or friction reducing formulations that include a mixture of at least one first ionic liquid and at least one ashless antiwear compound. The ashless antiwear compound can be a second ionic liquid or an ashless thiophosphate compound. The formulation desirably provides synergistic anti-wear and/or friction reducing properties. The first IL can be a monocationic ionic liquid or a dicationic ionic liquid. The second IL is a dicationic ionic liquid. The ashless thiophosphate is desirably a thiophosphate, such as a fluorothiophosphate (FTP), an alkylphosphorofluoridothiolate, or an alkylthioperoxydithiophosphate. Antiwear and/or friction reduction formulations comprising the above mixtures diluted up to 25% by weight in a base oil.
摘要:
A powder medicament mouthpiece comprising at least one section of through suction tube (1) and a filter (2). One end of the suction tube is a medicament inlet, and the other end (16a) is a suction outlet. The filter (2) is arranged within the suction tube (1). The powder medicament mouthpiece can be connected to multiple models of dry powder inhalers to separate powder medicament from dry powder, and allows for significantly improved efficacy.
摘要:
A system and methods are provided for removal of undesired portions of a fruit or vegetable, such as removal of calyxes from strawberries before they are flash frozen. An automated process for high-throughput fruit or vegetable calyx removal includes a loading system, an identification system, and a removal system. The loading system is configured to transport the fruit or vegetable through the automated process. The loading system may also orient the fruits or vegetables along an axis of the fruit and or align the fruit or vegetables in a desired pattern, orientation, and/or arrangement. The identification system is configured to locate the calyx and determines calyx position data and an optimal cutting path for individual fruit. The removal system uses data received from the identification system to separate the calyx from the fruit or vegetable.
摘要:
A filtering powdered medicament inhaler comprising a base (1) and an upper base (2). The upper base (2) has arranged therein a separator (62), which is connected at the bottom to a pressure groove (63). The upper base (2) has arranged thereon a hollow tube exterior connector (10) matching a suction tube (131). The hollow tube (19a) and a cavity (9) on one side of the separator (62) are interconnected via conduit (18), or, the hollow tube (19a) is extended for about 8 centimeters to form a mouthpiece. The upper base (2) has arranged in the cavity (9) thereof a filter (121). The base (1) is provided with an external base cover (72) which covers a press-button (5a) so as to reduce air flow into the cavity (9). The medicament inhaling conduit of the inhaler is relatively sealed and allows for rapid entrainment of a sufficient dosage of powdered medicament.
摘要:
Microfluidic, electrochemical devices are described. The microfluidic, electrochemical device comprises one or more electrode(s) on a substrate and a patterned porous, hydrophilic layer having a fluid-impermeable barrier which substantially permeates the thickness of the porous, hydrophilic layer and defines boundaries of one or more hydrophilic channels within the patterned porous, hydrophilic layer, wherein the hydrophilic channel(s) comprises a hydrophilic region which is in fluidic communication with the electrode(s). In some embodiments, the electrodes comprise a working electrode, a counter electrode, and a reference electrode. In some embodiments, the microfluidic, electrochemical device further comprises a fluid sink. The method of assembling the microfluidic, electrochemical device is described. The method of using the device for electrochemical analysis of one or more analytes is also described.
摘要:
Self-regulating pressure source. The pressure source includes a chamber enclosing a chemical monopropellant. A moveable boss is attached to a deformable membrane sealing an air chamber, the moveable boss and air chamber being disposed within the chamber. A catalyst is disposed around the membrane so as to be covered by the boss in a retracted position so that the monopropellant is broken down by the catalyst to produce a gas. The gas pressure will increase within the chamber causing air in the air chamber to compress thereby to pull the boss into the retracted position to cover the catalyst thereby to regulate the pressure within the chamber. The self-regulating pressure source is particularly suited to power fluidic elastomeric actuators.
摘要:
Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and z are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.